文献速递贫血与红细胞疾病

混合型自身免疫性溶血性贫血:流行病学、临床特征、治疗与结局的系统综述

Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes.
PubMed 文献 · Am J Hematol · 2025-05-20

该系统综述采用严格诊断标准纳入35项研究共81例混合型自身免疫性溶血性贫血患者,中位年龄45岁,女性占优(2.25:1)。自身免疫病是最常见基础病因,中位最低血红蛋白5.6 g/dL;糖皮质激素最常用,但仅43%缓解,37%呈慢性溶血,死亡率达11%。

要点

  • 混合型AIHA中位年龄45岁,女性与男性比例2.25:1。
  • 中位最低血红蛋白5.6 g/dL,自身免疫病为最常见基础病因。
  • 糖皮质激素最常用,仅43%缓解,37%慢性溶血,死亡率11%。

核心结论

  • 混合型AIHA诊断与治疗方式差异大,亟需标准化诊断标准、更早联合治疗及探索创新疗法。
  • 未来需前瞻性多中心研究以改进疾病识别、优化治疗策略并改善患者结局。

研究设计与样本

  • 系统文献综述,采用严格诊断标准,纳入35项研究共81例混合型AIHA患者。

主要发现

  • 中位年龄45岁,女性与男性比例为2.25:1。
  • 自身免疫病为最常见基础病因,其次为血液系统恶性肿瘤和感染。
  • 中位最低血红蛋白为5.6 g/dL。
  • 糖皮质激素为最常见治疗,仅43%患者达到缓解,37%出现慢性溶血,死亡率达11%。
  • 许多患者需要多线治疗,包括利妥昔单抗和细胞毒药物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 诊断标准存在差异且数据有限。
  • 诊断与治疗方式存在显著差异。
  • 需未来前瞻性多中心研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mixed autoimmune hemolytic anemia (AIHA) is a rare and clinically complex hematologic disorder defined by the simultaneous presence of both warm and cold autoantibodies, resulting in severe and often treatment-resistant hemolysis. Due to variability in diagnostic criteria and limited data, a comprehensive understanding of its epidemiology, clinical characteristics, and management remains incomplete. To address these gaps, we performed a systematic literature review employing stringent diagnostic criteria to evaluate epidemiologic patterns, clinical features, and therapeutic outcomes. Our analysis included 81 patients identified across 35 studies, revealing a median age of 45 years and a notable female predominance (2.25:1). Autoimmune diseases constituted the most frequent underlying etiology, followed by hematologic malignancies and infections. Patients exhibited significant anemia, with median nadir hemoglobin levels reaching 5.6 g/dL. Corticosteroids represented the most common therapeutic intervention; however, only 43% of patients achieved remission, while 37% experienced chronic hemolysis, and mortality reached 11%. Many patients required multiple lines of therapy, including rituximab and cytotoxic agents, highlighting the disease's refractory nature and management complexity. The substantial variability in diagnostic and therapeutic approaches emphasizes an urgent need for standardized diagnostic criteria, earlier integration of combination therapies, and exploration of innovative treatment modalities. Future prospective, multicenter studies are essential to refine disease recognition, optimize therapeutic strategies, and ultimately improve patient outcomes in mixed AIHA.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jacobs JW, Raza S, Clark LM, et al. Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes. Am J Hematol. 2025. PMID: 40392014. doi:10.1002/ajh.27721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。